MLL
RLMD icon

Moody Lynn & Lieberson’s Relmada Therapeutics RLMD Stock Holding History

Moody Lynn & Lieberson’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-65,055
Closed -$2.41M – 231
2022
Q3 		$2.41M Buy
+65,055
New +$1.8M 0.23% 78

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Moody Lynn & Lieberson's RLMD Position: Q4 2022 in Review

Moody Lynn & Lieberson sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 65,055 shares — an estimated $2.41M sold.

Moody Lynn & Lieberson first reported a position in RLMD in Q3 2022 and held it in 1 quarter. The position peaked at $2.41M in Q3 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

  • Moody Lynn & Lieberson reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Moody Lynn & Lieberson sold 65,055 Relmada Therapeutics shares in Q4 2022, an estimated $2.41M.
  • Moody Lynn & Lieberson first reported a position in Relmada Therapeutics in Q3 2022 and held it in 1 quarter.
  • Moody Lynn & Lieberson's Relmada Therapeutics position peaked at $2.41M in Q3 2022.
  • 110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on Moody Lynn & Lieberson's 13F filing for Q4 2022, filed 1 Feb 2023.